DanCann Pharma was founded in 2018 and is a Danish pharmaceutical company. DanCann Pharma focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in a broad range of disease areas. The company makes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.

Quotes for DanCann Pharma A/S

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Jeppe Krog Rasmussen

Chairperson of the Board

  • Carsten Trads

Board

  • Jeppe Krog Rasmussen
  • Alexander Schoeneck
  • Christian Carlsen
  • Tue Østergaard

Largest Owners

Name Capital % Votes % Date
Nordic Growth Opportunities 2 10,44 10,44 2023-10-04
Jeppe Krog Rasmussen 9,10 9,10 2022-12-31
Sellers of CannGros ApS 7,85 7,85 2021-10-05
Alexander Schoeneck 6,21 6,21 2022-06-30
Futur Pension 5,56 5,56 2021-09-30
Morten Martinsen 1,41 1,41 2021-12-30
Hansen & Nytoft Invest Aps 1,34 1,34 2021-08-19
Tue Østergaard 1,28 1,28 2022-12-31
Vavi Invest Aps 0,88 0,88 2021-08-19
Carsten Trads 0,63 0,63 2022-12-31
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

Key Numbers

*Compiled data from Millistream